Tycho Peterson, an analyst from Jefferies, maintained the Buy rating on Danaher (DHR – Research Report). The associated price target was lowered to $230.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tycho Peterson has given his Buy rating due to a combination of factors influencing Danaher’s performance and future outlook. The company has demonstrated resilience in managing macroeconomic challenges, such as tariffs, by leveraging cost-cutting measures and strategic adjustments to maintain its operational margin targets. This adaptability suggests a strong potential for earnings growth, with the EPS guidance indicating a bullish scenario reaching up to $8 by 2025 and $9 by 2026.
Furthermore, the positive trends in the bioprocessing segment, which showed significant growth, contribute to rebuilding confidence in the company’s management and market position. The company’s strategic positioning in high-growth areas, such as bioproduction and life sciences, coupled with its ability to mitigate external pressures, supports the expectation of share price appreciation. These factors collectively underpin Peterson’s optimistic outlook and Buy rating for Danaher’s stock.
According to TipRanks, Peterson is a 4-star analyst with an average return of 3.6% and a 50.32% success rate. Peterson covers the Healthcare sector, focusing on stocks such as Exact Sciences, Qiagen, and Bruker.